Trial document



drksid header

  DRKS00022409

Trial Description

start of 1:1-Block title

Title

Single Center Prospective Controlled Follow-up Study of COVID-19 Patients District Konstanz (FSC19-KN)

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

FSC19-KN

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

http://www.ZKS-HegauBodensee.de

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

It is a prospective single-center research project for the follow-up of SARS-CoV-2 positive patients in the district of Konstanz. Currently, as part of the coronavirus (SARS-CoV-2) pandemic, patients with SARS-CoV-2 infection are inpatients in the clinics of the health network of the district of Konstanz with the locations Singen (Hegau-Bodensee Klinikum) and Konstanz (Konstanz Clinic) treated.
So far, there is little data on the long-term effects of SARS-CoV-2 infection. As part of this research project, the course of the disease in these patients should be monitored in order to identify and treat late complications at an early stage.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Participants will be patients from the Constance district. Potential participants have given their consent to participate in the study. The patients are identified by the health department of the district of Konstanz. Patients with a positive molecular biological detection (PCR) for SARS-CoV-2 are included.
The patients are written to and asked to give their consent to clinical follow-up. If the consent and the data protection release are available, the clinical parameters of the patients are recorded. For the control group, volunteer test persons are sought by newspaper advertisements or flyers and their consent to participate is obtained.
The patients and test persons are invited to an initiation visit. Standardized clinical parameters are collected, the questionnaires are filled out together and a SARS-CoV-2 antibody test is carried out. The follow-up period is 5 years, whereby the clinical events (hospitalization) are queried annually by telephone and the questionnaires are documented in the telephone interview.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

No

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00022409
  •   2020/12/03
  •   [---]*
  •   yes
  •   Approved
  •   20-1020, Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   COVID-19
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   SARS-CoV-2 positive patients receive a physical examination including measurement of breathing rate, heart rate, blood pressure, oxygen saturation and a SARS-CoV-2 antibody test during the initial visit. In addition, a 6-minute walking test is performed and the patient answers 2 questionnaires (EQ-5D-5L and Cardiomyopathy in Kansas City (KCCQ-12)). During the annual surveys, the need for hospitalization is asked by telephone and the 2 questionnaires (EQ-5D-5L and Cardiomyopathy in Kansas City (KCCQ-12)) are filled out.
  •   Subjects without a positive SARS-CoV-2 test and without contact to SARS-CoV-2 positive patients receive a physical examination including measurement of the breathing rate, heart rate, blood pressure, oxygen saturation and a SARS-CoV-2 antibody test during the initial visit. In addition, a 6-minute walk test is performed and the patient answers 2 questionnaires (EQ-5D-5L and Cardiomyopathy in Kansas City (KCCQ-12)). During the annual surveys, the need for hospitalization is asked by telephone and the 2 questionnaires (EQ-5D-5L and Cardiomyopathy in Kansas City (KCCQ-12)) are filled out.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Epidemiological study
  •   Non-randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Other
  •   Prognosis
  •   Parallel
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Hospitalization (assessment of adverse events) on annually basis.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Quality of life measured by questionnaires EQ-5D-5L and Cardiomyopathy in Kansas City (KCCQ-12)

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Planned
  •   2021/01/01
  •   400
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Inclusion Criteria of SARS-CoV-2 positive patients
Patient must meet ALL of the following criteria.
1. Positive test for SARS-CoV-2 by PCR
2. Signed informed consent and privacy policy
Inclusion Criteria of the control group
Volunteer must meet ALL of the following criteria.
1. No contact to SARS-CoV-2 positive patients
2. negative SARS-CoV-2 antibody test
3. Signed informed consent and privacy policy

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Exclusion Criteria for all Participants
Patient / Volunteer will be excluded if ANY of the following conditions apply:
1. Patient / Volunteer age < 18 years
2. Patient / Volunteer who are unable to read the information and understand the nature of the study
3. Patient / Volunteer participate in any other clinical study

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Hegau-Bodensee-Klinikum Singen
    • Mr.  PD Dr. med.  Marc  Kollum 
    • Virchow Str. 10
    • 78224  Singen am Hohentwiel
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Hegau-Bodensee-Klinikum Singen
    • Mr.  PD Dr. med.  Marc  Kollum 
    • Virchow Str. 10
    • 78224  Singen am Hohentwiel
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Hegau-Bodensee-Klinikum Singen
    • Mr.  PD Dr. med.  Marc  Kollum 
    • Virchow Str. 10
    • 78224  Singen am Hohentwiel
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Deutsche Forschungsgemeinschaft
    • Kennedyallee 40
    • 53175  Bonn
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting planned
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.